Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds

January 2017

Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.

Adlyxin (lixisenatide) is the sixth GLP-1 agonist for diabetes. Think of it as similar to Byetta...but it's once-daily instead of BID.

Soliqua is the first insulin/GLP-1 agonist combo to hit shelves. It contains Lantus (insulin glargine U-100) plus Adlyxin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote